Treatment Registry

Company

EmbraceRX

EmbraceRX publishes compounded semaglutide, oral semaglutide and compounded tirzepatide, from $117 to $323 a month.

  • 4 programs
  • 3 molecules
  • 4 readings

Read from embracerx.co on September 2, 2026. This page records what the company publishes. It is not a review and takes no position on the company.

Go to EmbraceRX

Visit EmbraceRX

We earn nothing from this link. EmbraceRX has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.

What it costs

Compounded semaglutideInjection, vial$117

first month, including the required fees on record · Semaglutide + B12, entry-level dose, starting price

Oral semaglutideOral tablet$171

first month, including the required fees on record · Semaglutide capsules, starting price

Compounded tirzepatideInjection, vial$179

first month, including the required fees on record · High-dose tirzepatide, starting price

Compounded tirzepatideOral tablet$323

first month, including the required fees on record · Tirzepatide capsules, starting price

Terms

Not yet checked: pharmacy, membership, consultation fee and states.

Terms can differ between this company’s programs; each entry carries its own.

Programs

EntryProviderFormPer month
at its shortest term		Link
TR-0524EmbraceRXInjection, vial$117
Semaglutide + B12, entry-level dose, starting price		Record
TR-0526EmbraceRXOral tablet$171
Semaglutide capsules, starting price		Record
TR-0525EmbraceRXInjection, vial$179
High-dose tirzepatide, starting price		Record
TR-0527EmbraceRXOral tablet$323
Tirzepatide capsules, starting price		Record

Notes

Recorded against this company rather than one program.

September 2, 2026

  1. 1. Each product's price is described as 'Starting from $X' with 'Price shown at checkout. Dose selection on the next step' — the exact per-dose price ladder beyond the starting figure is not published on these pages. The FAQ has a 'What states do we serve?' question with no rendered answer (accordion content not present in this tool's output), so states left not-found rather than guessed. Oral tirzepatide capsules are recorded under the enum's 'compounded tirzepatide' + form 'oral-tablet' since there is no distinct 'oral tirzepatide' enum value and no FDA-approved oral tirzepatide brand exists; the product page itself calls it 'Oral dual GIP/GLP-1 receptor agonist' with no brand name, consistent with a compounded oral formulation. Site prominently disclaims no association with Novo Nordisk/Eli Lilly brand products and states it does not supply Wegovy/Ozempic/Ozempic/Mounjaro/Saxenda.

Before you act

Cite this

Treatment Registry. (2026). EmbraceRX: recorded programs and prices. Last verified September 2, 2026. Retrieved [your access date], from https://treatmentregistry.com/providers/embrace-rx